Deal Building From Testing The Water To Hitting The Market
Source: Life Science Leader
By Suzanne Elvidge, Contributing Writer
Follow Me On Twitter @suzannewriter
In 2017, UK-based gene and cell therapy company Oxford BioMedica won a key contract from Novartis to provide the commercial and clinical supply of lentiviral vectors used to produce Big Pharma’s CAR-T cell therapy Kymriah (tisagenlecleucel). The deal could be worth upwards of $100 million over its three-year span.
access the Magazine Article!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.
Subscribe to Life Science Leader
X
Subscribe to Life Science Leader
This website uses cookies to ensure you get the best experience on our website. Learn more